TC
ATRS

TFS Capital’s Antares Pharma, Inc. ATRS Stock Holding History

TFS Capital’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-16,613
Closed -$53K – 439
2017
Q2 		$53K Buy
16,613
+1,813
+12% +$5.14K 0.02% 588
2017
Q1 		$42K Sell
14,800
-11,716
-44% -$28.2K 0.01% 633
2016
Q4 		$62K Sell
26,516
-66,083
-71% -$126K 0.02% 675
2016
Q3 		$156K Buy
+92,599
New +$113K 0.04% 595
2016
Q1 		– Sell
-17,642
Closed -$21K – 1134
2015
Q4 		$21K Sell
17,642
-122,000
-87% -$170K ﹤0.01% 727
2015
Q3 		$237K Buy
139,642
+25,212
+22% +$49.4K 0.02% 708
2015
Q2 		$238K Buy
114,430
+13,977
+14% +$33.9K 0.02% 717
2015
Q1 		$272K Sell
100,453
-22,965
-19% -$58.3K 0.03% 716
2014
Q4 		$317K Sell
123,418
-39,989
-24% -$89.8K 0.03% 713
2014
Q3 		$299K Buy
163,407
+118,521
+264% +$258K 0.03% 746
2014
Q2 		$120K Buy
+44,886
New +$135K 0.01% 1031

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TFS Capital's ATRS Position: Q3 2017 in Review

TFS Capital sold out of Antares Pharma, Inc. (ATRS) in Q3 2017, closing a stake of 16,613 shares — an estimated $53K sold.

TFS Capital first reported a position in ATRS in Q2 2014 and held it in 11 quarters. The position peaked at $317K in Q4 2014. 103 funds tracked by Wall St. Rank hold ATRS as of Q3 2017.

  • TFS Capital reported no remaining Antares Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 16,613 Antares Pharma, Inc. shares in Q3 2017, an estimated $53K.
  • TFS Capital first reported a position in Antares Pharma, Inc. in Q2 2014 and held it in 11 quarters.
  • TFS Capital's Antares Pharma, Inc. position peaked at $317K in Q4 2014.
  • 103 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.